| Available antirelapse (hypnozoiticidal) agents* | Exclusion criteria | Antimalarial (blood schizonticidal) regimen | G6PD activity | |||
| >70% | 30-70% | <30% | Unavailable | |||
| Primaquine¶ |
| Chloroquine or an artemisinin combination regimen | 0.5 mg base/kg once daily for 14 days (total dose 7 mg/kg) | 0.5 mg base/kg once daily for 14 days (total dose 7 mg/kg) | 0.75 mg base/kg once weekly for 8 weeks (total dose 6 mg/kg)Δ | 0.25 mg base/kg once daily for 14 days (total dose 3.5 mg/kg)◊ |
| Tafenoquine |
| Chloroquine | Adult dosing (>16 years): 300 mg single dose Pediatric dosing§:
| Not recommended | Not recommended | Not recommended |
G6PD: glucose-6-phosphate dehydrogenase.
* Patients treated with primaquine or tafenoquine should be counseled to report signs of drug-induced hemolysis (dark urine, fatigue, or shortness of breath); in such cases, the drug should be discontinued.
¶ The gastrointestinal tolerability of primaquine can be improved by administering with food.
Δ Patients should be evaluated on day 7 to evaluate for adverse effects.
◊ This regimen is sufficient for preventing P. ovale relapses and is efficacious for prevention of P. vivax relapse for infection acquired in temperate areas and areas of lower relapse periodicity. Refer to the UpToDate topic on nonfalciparum malaria for further discussion.
§ Pediatric formulation licensed in Australia but not in the United States.